Another promising compound, UNC1999, targets both EZH1 and EZH2 to reduce H3K27me3 at the SLFN11 promoter, thereby sensitizing HCC cells to sorafenib and enhancing anti-tumor effects [56]. The gene discussed is EZH2; the disease is neoplasm.